Skip to main content
AAPS Open
Fig. 1 | AAPS Open

Fig. 1

From: Pharmacokinetic and pharmacodynamic analyses of terlipressin in patients with hepatorenal syndrome

Fig. 1

Structural pharmacokinetic model for terlipressin and its active metabolite lysine-vasopressin. CLA, total body clearance for terlipressin; CLM/Fm and VM/Fm, apparent volume of central compartment and clearance for lysine-vasopressin; IV, intravenous; QA, intercompartmental flow rate; V1A, central volume of distribution for terlipressin; V2A, peripheral volume of distribution for terlipressin

Back to article page